Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

by Inbal Uri, Simona Grozinsky-Glasberg
Published 2018-07-01

Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing’s syndrome in a medullary thyroid carcinoma patient

by Hashem Bseiso, Naama Lev-Cohain, David J Gross, Simona Grozinsky-Glasberg
Published 2016-10-01

Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)

by Alexandre Chicheportiche, Faozi Artoul, Arnon Schwartz, Simona Grozinsky-Glasberg, Amichay Meirovitz, David J. Gross, Jeremy Godefroy
Published 2018-06-01

Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management

by Alexandre Chicheportiche, Simona Ben-Haim, Simona Grozinsky-Glasberg, Kira Oleinikov, Amichay Meirovitz, David J. Gross, Jeremy Godefroy
Published 2020-01-01

Predictive power of the post-treatment scans after the initial or first two courses of [177Lu]-DOTA-TATE

by Alexandre Chicheportiche, Simona Grozinsky-Glasberg, David J. Gross, Yodphat Krausz, Asher Salmon, Amichay Meirovitz, Nanette Freedman, Jeremy Godefroy
Published 2018-12-01

Can a penalized-likelihood estimation algorithm be used to reduce the injected dose or the acquisition time in 68Ga-DOTATATE PET/CT studies?

by Alexandre Chicheportiche, Elinor Goshen, Jeremy Godefroy, Simona Grozinsky-Glasberg, Kira Oleinikov, Amichay Meirovitz, David J. Gross, Simona Ben-Haim
Published 2021-02-01

Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study

by Alexandre Chicheportiche, Moshe Sason, Jeremy Godefroy, Yodphat Krausz, Mahmoud Zidan, Kira Oleinikov, Amichay Meirovitz, David J. Gross, Simona Grozinsky-Glasberg, Simona Ben-Haim
Published 2021-08-01